Resonance Health has received a $732,851 refund from the Australian Taxation Office, reflecting its FY2025 R&D tax incentive claim net of income tax payable. This cash inflow strengthens the company’s financial position ahead of its March quarterly report.
- Received $732,851 net R&D tax incentive refund for FY2025
- Refund reflects $832,959 R&D claim minus $100,108 income tax payable
- Cash boost to be reflected in March 2026 quarterly report
- Company specialises in AI-enhanced MRI diagnostic software
- Ongoing development of liver and heart disease assessment tools
R&D Tax Incentive Refund Strengthens Financial Position
Resonance Health Limited (ASX:RHT), an Australian healthcare technology company, has announced receipt of a $732,851 refund from the Australian Taxation Office. This refund represents the net benefit of the company’s Research and Development (R&D) tax incentive claim for the 2025 financial year, after offsetting income tax payable.
The gross R&D tax incentive claimed was $832,959, with income tax liabilities for the year amounting to $100,108. The resulting net refund will bolster Resonance Health’s cash reserves, a positive development ahead of the company’s upcoming March 2026 Appendix 4C and Quarterly Activities Report.
Innovative Medical Imaging Technologies at the Core
Resonance Health is recognised globally for its advanced MRI-based diagnostic software, which assists clinicians and pharmaceutical companies in managing diseases and conducting clinical trials. Its portfolio includes several regulatory-cleared Software-as-Medical Devices (SaMDs), many enhanced with artificial intelligence to improve diagnostic accuracy and efficiency.
Key products include FerriScan®, the gold standard for non-invasive liver iron concentration assessment, and FerriSmart®, an AI-driven real-time LIC assessment tool. The company also offers HepaFatScan® and HepaFatSmart® for liver fat evaluation, LiverSmart® which combines multiple assessments into a consolidated report, and CardiacT2*, a leading MRI method for heart iron loading analysis.
Pipeline and Clinical Trials Expansion
Beyond its current product suite, Resonance Health is advancing the MRI Liver Fibrosis Project, aiming to non-invasively assess liver fibrosis progression. The company also operates a clinical trials business, including site management through TrialsWest, supporting pharmaceutical research and development.
This R&D tax incentive refund not only reflects the company’s commitment to innovation but also provides tangible financial support to continue developing cutting-edge diagnostic tools that could shape future disease management.
Bottom Line?
This cash injection from R&D incentives underscores Resonance Health’s ongoing investment in innovation, setting the stage for its next growth phase.
Questions in the middle?
- How will the increased cash reserves impact Resonance Health’s R&D pipeline and product development timelines?
- What are the prospects for regulatory approvals and market adoption of the MRI Liver Fibrosis Project?
- How might the company’s clinical trials business contribute to revenue growth in the near term?